Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Fernando Bernabeu"'
Autor:
Roberto Jiménez Gil, Jorge Bercial Arias, Alberto Miñano Pérez, Fernando Bernabeu Pascual, Eugenio Sansegundo Romero
Publikováno v:
Journal of Vascular Surgery. 44:1114-1116
The absence of the inferior vena cava is an uncommon congenital anomaly and can be misdiagnosed. We report a 14-year-old boy initially admitted as a result of a painful abdominal mass; after admission, he experienced a deep venous thrombosis in his l
Autor:
Inmaculada Montañés, Fernando Bernabeu, José M. López-Novoa, Inmaculada Millás, Dulcenombre Gómez-Garre, Antonio López-Farré
Publikováno v:
Scopus-Elsevier
Renal effects and mesangial cell contraction induced by endothelin are mediated by PAF. The recently discovered vasoactive peptide endothelin and platelet activating factor (PAF) share similar renal effects. The purpose of the present series of exper
Autor:
Eva Girona, Fernando Bernabeu, José Gayá, José Manuel Navarro-Rodríguez, Francisco Pérez-Vicente, Ana Sánchez-Romero, Santiago Gimena, Rafael Calpena-Rico, Fernando Candela, Ana Fernández-Frías, Antonio Arroyo, David Martínez-Marín, Pilar Serrano
Publikováno v:
Cirugía Española. 78:119-120
Publikováno v:
Europe PubMed Central
1. Endothelin (ET) has been shown to reduce glomerular filtration rate (GFR) and renal blood flow (RBF) and may therefore be a possible mediator of the reduction of GFR and RBF observed in post-ischaemic acute renal failure. 2. We infused a specific
Autor:
Gil, Roberto Jiménez, Pérez, Alberto Miñano, Arias, Jorge Bercial, Pascual, Fernando Bernabeu, Romero, Eugenio Sansegundo
Publikováno v:
Journal of Vascular Surgery; Nov2006, Vol. 44 Issue 5, p1114-1116, 3p
Autor:
Pierre Braquet, Fernando Bernabeu, José M. López-Novoa, Antonio López-Farré, Paloma Perez-Rodrigo, Santiago Ramón y Cajal, Dulcenombre Gómez-Garre
Publikováno v:
Europe PubMed Central
ResearcherID
Scopus-Elsevier
ResearcherID
Scopus-Elsevier
1. We have studied the effect of inhibiting the interaction of platelet-activating factor with its receptor by using two structurally different antagonists BN-52021 (1 mg/kg, intraperitoneally) and alprazolam (1 and 5 mg/kg, intraperitoneally) on the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b47350b186e7e37ac399b36f2dfe26b
http://europepmc.org/abstract/med/2176942
http://europepmc.org/abstract/med/2176942